Island Pharma

Dengue fever is a major global health concern, primarily spread by the Aedes mosquito in tropical and subtropical regions. It affects millions annually, significantly burdening healthcare systems and impacting daily life with severe symptoms.

ISLA-101 is the lead asset that is being repurposed for the prevention and treatment of dengue fever and other mosquito (or vector) borne diseases. Based on studies at Monash University, it has been demonstrated that ISLA-101 prevents nuclear entry of a particular viral protein into the host cell nucleus, preventing the propagation of the viral infection. As such, ISLA-101 is designed to act as an inhibitor to target the stages and proteins of Flaviviruses.

As climate change expands mosquito habitats, the urgency for effective dengue prevention and control intensifies, making ISLA-101 an increasingly critical component of global health strategies.

Website: www.islandpharmaceuticals.com